Outcome of bilateral deep brain subthalamic stimulation in patients carrying the R1441G mutation in the LRRK2 dardarin gene

Neurosurgery

Volumn 62, Issue 4, 2008, Pages 857-862

  Gómez Esteban, Juan C ^a,b   Lezcano, Elena ^a,b   Zarranz, Juan J ^a,b   González, Carmen ^b   Bilbao, Gaizka ^a,b   Lambarri, Imanol ^a   Rodríguez, Olivia ^a   Garibi, Jesús ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Dardarin; Deep brain stimulation; Genetics; Leucine rich repeat kinase 2; LRRK2; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; GENE MUTATION; HETEROZYGOTE; HUMAN; IDIOPATHIC DISEASE; MOTOR PERFORMANCE; PARKINSON DISEASE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; STROKE; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; MUTATION;

ADULT; DEEP BRAIN STIMULATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SUBTHALAMUS; TREATMENT OUTCOME;

EID: 48949119521     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.neu.0000318171.82719.35     Document Type: Article

References (35)

1. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M: Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 57:762-765, 2005.
2. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ: PET in LRRK2 mutations: Comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128:2777-2785, 2005.
3. Benabid AL, Krack PP, Benazzouz A, Limousin P, Koudsie A, Pollak P: Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: Methodologic aspects and clinical criteria. Neurology 55:S40-S44, 2000.
4. Capecci M, Passamonti L, Annesi F, Annesi G, Bellesi M, Candiano IC, Ricciuti R, Iacoangeli M, Scerrati M, Zappia M, Tarantino P, De Marco EV, Civitelli D, Carrideo S, Provinciali L, Ceravolo MG, Quattrone A: Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene. Mov Disord 19:1450-1452, 2004.
5. Defer GL, Widner H, Marié RM, Rémy P, Levivier M: Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14:572-584, 1999.
6. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, German Parkinson Study Group, Neurostimulation Section: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355:896-908, 2006.
7. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V, Italian Parkinson Genetics Network: A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365:412-415, 2005.
8. Ford B, Winfield L, Pullman SL, Frucht SJ, Du Y, Greene P, Cheringal JH, Yu Q, Cote LJ, Fahn S, McKhann GM 2nd, Goodman RR: Subthalamic nucleus stimulation in advanced Parkinson's disease: Blinded assessments at one year follow up. J Neurol Neurosurg Psychiatry 75:1255-1259, 2004.
9. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, Tsuji S, Obata F: An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol, 57:918-921, 2005.
10. Gaig C, Ezquerra M, Marti MJ, Muñoz E, Valldeoriola F, Tolosa E: LRRK2 mutations in Spanish patients with Parkinson disease: Frequency, clinical features, and incomplete penetrance. Arch Neurol 63:377-382, 2006.
11. Goldwurm S, Di Fonzo A, Simons EJ, Rohé CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V: The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42:e65, 2005.
12. González-Fernández MC, Lezcano E, Ross OA, Gómez-Esteban JC, Gómez-Busto F, Velasco F, Alvarez-Alvarez M, Rodríguez-Martínez MB, Ciordia R, Zarranz JJ, Farrer MJ, Mata IF, de Pancorbo MM: Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord 13:509-515, 2007.
13. Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J: Clinical traits of LRRK2-associated Parkinson's disease in Ireland: A link between familial and idiopathic PD. Parkinsonism Relat Disord 11:349-352, 2005.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184, 1992.
15. Infante J, Rodríguez E, Combarros O, Mateo I, Fontalba A, Pascual J, Oterino A, Polo JM, Leno C, Berciano J: LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett, 13:224-226, 2005.
16. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M: Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations. Am J Hum Genet 76:672-680, 2005.
17. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW: Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: Clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796, 2005.
18. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger AL, Guimaraes J, Bonnet AM, Agid Y, Dürr A, Brice A, French Parkinson's Disease Genetics Study Group: G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58:784-787, 2005.
19. Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Dürr A, Brice A, French Parkinson's Disease Genetics Study Group, Bonnet AM, Borg M, Broussolle E, Damier P, Destée A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, Vérin M: LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 64:425-430, 2007.
20. Lezcano E, Gómez-Esteban JC, Zarranz JJ, Alcaraz R, Atarés B, Bilbao G, Garibi J, Lambarri I: Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: A clinicopathological case report. Mov Disord 19:973-977, 2004.
21. Marti Massó JF: Autosomal dominant familial Parkinson's disease. Presented at 10th International Congress of Parkinson's Disease and Movement Disorders, Kyoto, Japan, October 28-November 2, 2006.
22. Martínez-Martín P, Frades Payo B: Quality of life in Parkinson's disease: Validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol 245 [Suppl 1]:S34-S38, 1998.
23. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ: Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6:171-177, 2005.
24. Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V: LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 382:309-311, 2005.
25. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600, 2004.
26. Paisán-Ruíz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A, Rogaeva E: LRRK2 gene in Parkinson disease: Mutation analysis and case control association study. Neurology 65:696-700, 2005.
27. Pérez-Tur J, Marti Massó JF: Clinical and molecular findings in LRRK2 Spanish and UK families. Presented at the Movement Disorder Society, Berlin, June 7, 2005.
28. Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A: High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol 252:208-211, 2005.
29. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW: Lrrk2 and Lewy body disease. Ann Neurol 59:388-393, 2006.
30. Schüpbach M, Lohmann E, Anheim M, Lesage S, Czernecki V, Yaici S, Worbe Y, Charles P, Welter ML, Pollak P, Dürr A, Agid Y, Brice A: Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Mov Disord 22:119-122, 2007.
31. Spanaki C, Latsoudis H, Plaitakis A: LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67:1518-1519, 2006.
32. Tarsy D, Apetauerova D, Ryan P, Norregaard T: Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy. Neurology 61:247-249, 2003.
33. Wszolek ZK, Pfeiffer B, Fulgham JR, Parisi JE, Thompson BM, Uitti RJ, Calne DB, Pfeiffer RF: Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 45:502-505, 1995.
34. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A: A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65:741-744, 2005.
35. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607, 2004.